[Event Details]

• Recipients: The 2026 Nobel Prize in Chemistry has been awarded to Henri Kagan (Professor Emeritus at the French National Centre for Scientific Research) and Kenso Soai (Professor Emeritus at the Tokyo Institute of Technology) for their pioneering contributions to chiral molecule research.
• Chirality: Chirality refers to the property that molecular structures can be mirror images of each other but cannot be perfectly overlaid, analogous to left and right hands. This property determines how drug molecules interact with biological receptors.
• Core Breakthrough: Kagan first systematically laid the methodological foundation for asymmetric catalysis, enabling chemists to synthesize single-chirality molecules with high selectivity. Soai discovered and named the “Soai autocatalytic reaction,” providing crucial experimental evidence for the origin and amplification of chirality.
• Application Value: The research directly enabled the industrial production of key drugs including the antidepressant paroxetine and multiple receptor blockers for hypertension, benefiting hundreds of millions of patients annually.
• Prize: 11 million Swedish kronor (approximately USD 1 million), shared between the two laureates.

[Panoramic Analysis] First, the core value of chirality research lies in “determining molecular identity.” Chiral molecules often serve as the watershed between drug efficacy and side effects — the thalidomide tragedy of the 1960s in Europe stemmed precisely from the failure to separate mirror-image isomers. Kagan and Soai’s research provided humanity with the key to industrial-scale production of single-chirality molecules, safeguarding precision in modern pharmaceuticals from the source.

Second, the methodological spillover of asymmetric catalysis and the Soai autocatalytic reaction extends far beyond chemistry itself. Kagan’s foundational chiral-molecule ligand design logic has been widely applied across asymmetric hydrogenation, asymmetric oxidation and other catalytic systems, becoming a foundational tool of the pharmaceutical industry. The Soai autocatalytic reaction provides the only known experimental model for studying “chirality from nothing,” with profound implications for understanding chirality bias in the origin of life.

Third, the prize highlights the “long-cycle return” characteristic of fundamental chemistry research. From Kagan laying the foundation of asymmetric catalysis in the 1970s, to Soai’s discovery of the autocatalytic reaction in the 1990s, to today’s award, the field experienced a transformation cycle that took roughly decades to be fully absorbed by industry. It once again reminds science and industry that long-term investment in chirality science is essential, and neglecting basic research will cost the drug and materials industries their next upgrade window.

[Comparative Perspectives]

• Chair of the Nobel Committee for Chemistry: Praised the two scientists’ foundational contributions to “understanding the fundamental mechanism and amplification of chirality,” and emphasized the lasting impact of their work on pharmaceutical chemistry and the life sciences.
• European Federation of Pharmaceutical Industries and Associations: Highly praised the asymmetric catalysis techniques derived from Kagan’s work, stating that related methods have become a standard tool in industry-standard drug production processes.
• Chemical Society of Japan: Argued that the Soai autocatalytic reaction provides the only reproducible experimental model for “the chirality problem in the origin of life,” offering important insights into why life on Earth preferentially favors left-handed amino acids.
• Academic Community: Widely noted that the two scientists’ research spans “synthetic chemistry” and “mechanistic investigation,” reflecting a trend in which the Nobel Prize increasingly values “multi-dimensional, long-term impact.”

Editor: GoodInfo Global News Team